Rhumbline Advisers Buys 1,213 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Rhumbline Advisers increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,327 shares of the company’s stock after buying an additional 1,213 shares during the period. Rhumbline Advisers owned 0.18% of Amphastar Pharmaceuticals worth $3,242,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. raised its holdings in Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after acquiring an additional 398 shares in the last quarter. Asset Management One Co. Ltd. bought a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $78,000. KBC Group NV lifted its holdings in Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after buying an additional 650 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after purchasing an additional 301 shares during the period. Finally, Point72 DIFC Ltd grew its stake in Amphastar Pharmaceuticals by 85.9% during the third quarter. Point72 DIFC Ltd now owns 3,954 shares of the company’s stock worth $192,000 after purchasing an additional 1,827 shares during the period. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $28.43 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 9.48, a P/E/G ratio of 2.19 and a beta of 0.81. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $27.82 and a fifty-two week high of $53.96. The firm has a fifty day moving average price of $34.74 and a 200 day moving average price of $42.57.

Analyst Upgrades and Downgrades

A number of analysts have commented on AMPH shares. Piper Sandler lowered shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $66.00 to $36.00 in a research note on Tuesday, February 4th. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $50.33.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now owns 118,469 shares in the company, valued at $5,262,392.98. This represents a 5.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the sale, the director now owns 30,471 shares in the company, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.